ASH 2016 Annual Meeting Highlights in Myelodysplastic Syndromes


HDAC Inhibitors, Immunotherapy, and IDH2 Inhibitors
Guillermo Montalbán Bravo, MD

Begin


TGF-β Inhibitors, Anti-TLR-2 Antibodies, and Deaminase Inhibitors
David P. Steensma, MD, FACP

Begin


Hypomethylating Agents
Guillermo Garcia-Manero, MD

Begin


Immunomodulatory Drugs
Mikkael A. Sekeres, MD, MS

Begin

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved